Leucine-Rich Alpha-2-Glycoprotein: A Novel Predictor of Diastolic Dysfunction

Leucine-Rich Alpha-2-Glycoprotein: A Novel Predictor of Diastolic Dysfunction

Leucine-rich α2-glycoprotein (LRG1) mediates cardiac fibrocyte activation. It is upregulated in inflammatory conditions, atherosclerosis, and fibrosis. Diastolic dysfunction (DD) is due to myocardial fibrosis. This cross-sectional study examined the relationship between LRG1 and DD. Patients with sy...

Full description

Bibliographic Details
Main Authors:	Alexander Loch, Kok Leng Tan, Mahmoud Danaee, Iskandar Idris, Mei Li Ng
Format:	Article
Language:	English
Published:	MDPI AG 2023-03-01
Series:	Biomedicines
Subjects:	leucine-rich alpha-2-glycoprotein 1 (LRG1) diastolic dysfunction biomarker heart failure with preserved ejection fraction (HFpEF) cross-sectional study
Online Access:	https://www.mdpi.com/2227-9059/11/3/944

Similar Items

Leucine Supplementation Prevents the Development of Skeletal Muscle Dysfunction in a Rat Model of HFpEF
by: Paula Ketilly Nascimento Alves, et al.
Published: (2024-03-01)

Increased level of serum leucine-rich-alpha-2-glycoprotein 1 in patients with clear cell renal cell carcinoma
by: Shotaro Nakanishi, et al.
Published: (2024-04-01)

Mice with endothelial cell‐selective adhesion molecule deficiency develop coronary microvascular rarefaction and left ventricle diastolic dysfunction
by: Vadym Buncha, et al.
Published: (2023-03-01)

Elevation of a Novel Angiogenic Factor, Leucine-Rich- 2-Glycoprotein (LRG1), Is Associated With Arterial Stiffness, Endothelial Dysfunction, and Peripheral Arterial Disease in Patients With Type 2 Diabetes
by: Pek, Sharon L. T., et al.
Published: (2015)

Biomarkers of HFpEF: Natriuretic Peptides, High-Sensitivity Troponins and Beyond
by: Paolo Morfino, et al.
Published: (2022-08-01)

Diastolic Cardiac Function by MRI—Imaging Capabilities and Clinical Applications
by: El-Sayed H. Ibrahim, et al.
Published: (2021-12-01)

Association between Higher Circulating Leucine-Rich α-2 Glycoprotein 1 Concentrations and Specific Plasma Ceramides in Postmenopausal Women with Type 2 Diabetes
by: Alessandro Mantovani, et al.
Published: (2022-07-01)

The assessment of left ventricular diastolic function: guidance and recommendations from the British Society of Echocardiography
by: Shaun Robinson, et al.
Published: (2024-06-01)

Sacubitril/valsartan improves diastolic left ventricular stiffness with increased titin phosphorylation via cGMP-PKG activation in diabetic mice
by: Nozomi Furukawa, et al.
Published: (2024-10-01)

Impact of coronary microvascular dysfunction in heart failure with preserved ejection fraction: a meta‐analysis
by: Domenico D'Amario, et al.
Published: (2024-08-01)

Mural cell dysfunction contributes to diastolic heart failure by promoting endothelial dysfunction and vessel remodelling
by: Mandy O. J. Grootaert, et al.
Published: (2025-02-01)

Changes of leucine-rich alpha 2 glycoprotein could be a marker of changes of endoscopic and histologic activity of ulcerative colitis
by: Yuki Aoyama, et al.
Published: (2025-02-01)

A Review of Contemporary and Future Pharmacotherapy for Chronic Heart Failure in Children
by: Bibhuti B. Das
Published: (2024-07-01)

NADPH Oxidases in Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction
by: James P. Teuber, et al.
Published: (2022-09-01)

Impact of epicardial adipose tissue on cardiac function and morphology in patients with diastolic dysfunction
by: Alexander Schulz, et al.
Published: (2024-08-01)

The role of coronary microvascular dysfunction in the pathogenesis of heart failure with preserved ejection fraction
by: Becker Al-Khayatt, et al.
Published: (2024-05-01)

Targeting MuRF1 by small molecules in a HFpEF rat model improves myocardial diastolic function and skeletal muscle contractility
by: Volker Adams, et al.
Published: (2022-06-01)

Webtool to enhance the accuracy of diagnostic algorithms for HFpEF: a prospective cross‐over study
by: Jerremy Weerts, et al.
Published: (2023-12-01)

Hydrogen Sulfide as a Potential Therapy for Heart Failure—Past, Present, and Future
by: Kyle B. LaPenna, et al.
Published: (2021-03-01)

Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARAGON‐HF Proteomic Substudy
by: Natasha L. Patel‐Murray, et al.
Published: (2024-07-01)

Heart Failure With Preserved Ejection Fraction With CKD: A Narrative Review of a Multispecialty Disorder
by: Rahul N. Patel, et al.
Published: (2023-12-01)

The HFA‐PEFF score identifies ‘early‐HFpEF’ phenogroups associated with distinct biomarker profiles
by: Michiel T.H.M. Henkens, et al.
Published: (2022-06-01)

Relation of left atrial overload indices with prognostic endpoints in heart failure and preserved ejection fraction
by: Shiro Hoshida, et al.
Published: (2022-06-01)

Heart failure outcomes by left ventricular ejection fraction in a contemporary region‐wide patient cohort
by: Johan Sundström, et al.
Published: (2024-06-01)

Clinical Significance of Exercise Pulmonary Hypertension With a Negative Diastolic Stress Test for Suspected Heart Failure With Preserved Ejection Fraction
by: Jan Verwerft, et al.
Published: (2024-08-01)

Does the obesity-associated adipokine leucine-rich alpha2-glycoprotein 1 (LRG1) have a regulatory role of the skeletal muscle adaptive response to exercise?
by: Fariba Aghaei, et al.
Published: (2022-03-01)

Serum and Urine Biomarker Leucine-Rich Alpha-2 Glycoprotein 1 Differentiates Pediatric Acute Complicated and Uncomplicated Appendicitis
by: Mohit Kakar, et al.
Published: (2021-05-01)

Effects of Continuous Accelerated Pacing on Cardiac Structure and Function in Patients With Heart Failure With Preserved Ejection Fraction: Insights From the myPACE Randomized Clinical Trial
by: Kramer J. Wahlberg, et al.
Published: (2024-01-01)

The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists in the Management of Obesity-Related Heart Failure with Preserved Ejection Fraction: Benefits beyond What Scales Can Measure?
by: Paschalis Karakasis, et al.
Published: (2024-09-01)

Role of ejection fraction in patients at risk for advanced heart failure: insights from the HELP‐HF registry
by: Matteo Pagnesi, et al.
Published: (2024-02-01)

Serum Leucine-Rich Alpha-2 Glycoprotein 1 Levels in Patients with Lipodystrophy Syndromes
by: Michelle Krienke, et al.
Published: (2024-11-01)

Novel Relaxin Receptor RXFP1 Agonist AZD3427 in the Treatment of Heart Failure: A Phase 1a/b, First‐in‐Human, Randomized, Single‐Blind, Placebo‐Controlled Study
by: Kathleen Connolly, et al.
Published: (2024-08-01)

Differential Effects of Landiolol in Patients with Atrial Fibrillation and Atrial Tachycardia
by: Kengo Ayabe, et al.
Published: (2024-10-01)

Systemic Biomarkers and Unique Pathways in Different Phenotypes of Heart Failure with Preserved Ejection Fraction
by: Hao Chen, et al.
Published: (2022-10-01)

Circulating Monocyte Count as a Surrogate Marker for Ventricular-Arterial Remodeling and Incident Heart Failure with Preserved Ejection Fraction
by: Kuang-Te Wang, et al.
Published: (2020-05-01)

FK506-Binding Protein like (FKBPL) Has an Important Role in Heart Failure with Preserved Ejection Fraction Pathogenesis with Potential Diagnostic Utility
by: Michael Chhor, et al.
Published: (2023-02-01)

Mitochondrial Reactive Oxygen Species Dysregulation in Heart Failure with Preserved Ejection Fraction: A Fraction of the Whole
by: Caroline Silveira Martinez, et al.
Published: (2024-10-01)

The Possible Role of Rosuvastatin Therapy in HFpEF Patients—A Preliminary Report
by: Tomasz Urbanowicz, et al.
Published: (2024-11-01)

Exploring the Noninvasive Evaluation of the Pulmonary Pressure–Flow Relationship During Exercise
by: Mads J. Andersen, et al.
Published: (2024-08-01)

Right Ventricular‐Vascular Uncoupling Predicts Pulmonary Hypertension in Clinically Diagnosed Heart Failure With Preserved Ejection Fraction
by: Zheng‐Wei Chen, et al.
Published: (2024-01-01)